Aytu Biopharma (AYTU) Assets Average (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Assets Average data on file, last reported at $116.8 million in Q1 2026.

• On a quarterly basis, Assets Average fell 2.8% year-over-year to $116.8 million in Q1 2026; TTM through Mar 2026 was $116.8 million, a 2.8% decrease from a year earlier, with the FY2025 full-year figure at $121.1 million, down 4.83% from the prior year.
• Assets Average for Q1 2026 stood at $116.8 million, down from $123.5 million in the prior quarter.
• Over the last five years, Assets Average for AYTU reached as high as $196.3 million in Q1 2022 and fell as low as $116.0 million in Q4 2024.
• Historically, Assets Average has averaged $134.6 million across 5 years, with a median of $130.1 million in 2024.
• On a YoY basis, Assets Average climbed as much as 135.27% in 2022 and fell as far as 41.71% in 2022.
• Year by year, Assets Average stood at $145.7 million in 2022, then fell by 9.37% to $132.1 million in 2023, then dropped by 12.14% to $116.0 million in 2024, then climbed by 6.43% to $123.5 million in 2025, then dropped by 5.38% to $116.8 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $116.8 million in Q1 2026, $123.5 million in Q4 2025, and $124.6 million in Q3 2025.